EGFR and exanthem: Rash is the most common toxicity reported in patients treated with the anti-EGFR monoclonal antibodies cetuximab (Needle, 2002) and panitumumab (Schwartz et al, 2002), and in patients treated with the EGFR tyrosine kinase inhibitors gefitinib (Baselga et al, 2002) and erlotinib (Hidalgo et al, 2001), and its occurrence with these agents is occasionally severe.